SUN PHARMA ADVANCED RESEARCH COMPANY
|
SUN PHARMA ADVANCED RESEARCH COMPANY Last 5 Year Cashflow Statement History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|
| Profit Before Tax | ₹-343 Cr | ₹-387 Cr | ₹-223 Cr |
| Adjustment | ₹21 Cr | ₹-11 Cr | ₹6.99 Cr |
| Changes In working Capital | ₹-47 Cr | ₹-27 Cr | ₹141 Cr |
| Cash Flow after changes in Working Capital | ₹-369 Cr | ₹-425 Cr | ₹-74 Cr |
| Cash Flow from Operating Activities | ₹-360 Cr | ₹-429 Cr | ₹-69 Cr |
| Cash Flow from Investing Activities | ₹158 Cr | ₹392 Cr | ₹-548 Cr |
| Cash Flow from Financing Activities | ₹199 Cr | ₹42 Cr | ₹617 Cr |
| Net Cash Inflow / Outflow | ₹-3.38 Cr | ₹4.74 Cr | ₹-0.64 Cr |
| Opening Cash & Cash Equivalents | ₹5.33 Cr | ₹0.58 Cr | ₹1.22 Cr |
| Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | - | - |
| Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | - |
| Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - |
| Effect of Foreign Exchange Fluctuations | ₹0.01 Cr | ₹0.00 Cr | - |
| Closing Cash & Cash Equivalent | ₹1.96 Cr | ₹5.33 Cr | ₹0.58 Cr |
Compare Cashflow Statement of peers of SUN PHARMA ADVANCED RESEARCH COMPANY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUN PHARMA ADVANCED RESEARCH COMPANY | ₹7,758.8 Cr | 6.5% | 17.2% | 49.4% | Stock Analytics | |
| SAGILITY | ₹19,291.8 Cr | 2.1% | -1% | -6.8% | Stock Analytics | |
| PRIME FOCUS | ₹18,884.2 Cr | 16.6% | 5.7% | 104.5% | Stock Analytics | |
| SYNGENE INTERNATIONAL | ₹17,755.4 Cr | 0.9% | -0.3% | -33.8% | Stock Analytics | |
| INTERNATIONAL GEMOLOGICAL INSTITUTE | ₹15,629.1 Cr | 0.6% | -0.1% | -0.1% | Stock Analytics | |
| INDEGENE | ₹12,396.8 Cr | -0.9% | -0.8% | -11.6% | Stock Analytics | |
SUN PHARMA ADVANCED RESEARCH COMPANY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMA ADVANCED RESEARCH COMPANY | 6.5% |
17.2% |
49.4% |
| SENSEX | 0.7% |
4.4% |
-5.6% |
You may also like the below Video Courses